All In Biotech

Drug Trial Radar · NCT06236438

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 167 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

167

Actual

Start

Apr 10, 2024

Primary completion

Oct 2031

Study completion Oct 2031

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab plus chemotherapy versus pembrolizumab plus chemotherapy in participants with untreated metastatic non-squamous non-small cell lung cancer. Livmoniplimab is an investigational drug being developed for the treatment of NSCLC. There are 2 stages to this study. In Stage 1, there are 4 treatment arms. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug) + chemotherapy, budigalimab +chemotherapy, or pembrolizumab +chemotherapy. In Stage 2, there are 2 treatments arms. Participants will either receive livmoniplimab (optimized dose) in combination with budigalimab +chemotherapy or placebo in combination with pembrolizumab +chemotherapy. Chemotherapy consists of IV Infused pemetrexed + IV infused cisplatin or IV infused or injected carboplatin. Approximately 840 adult participants will be enrolled in the study across 200 sites worldwide. Stage 1: In cohort 1, participants will receive intravenously (IV) infused livmoniplimab (dose A)+ IV infused budigalimab, + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + IV Infused pemetrexed. In cohort 2, participants will receive livmoniplimab (dose B) + budigalimab + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed. In cohort 3, participants will receive budigalimab + chemotherapy for 4 cycles followed by budigalimab + pemetrexed . In cohort 4, participants will receive IV Infused pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed. Stage 2: In arm 1, participants will receive livmoniplimab (dose optimized) + budigalimab + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed. In arm 2, participants will receive IV Infused placebo + pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed. The estimated study duration is 55 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • LivmoniplimabDrug

    Intravenously (IV) Infusion

  • BudigalimabDrug

    IV Infusion

  • PembrolizumabDrug

    IV Infusion

  • PemetrexedDrug

    IV Infusion

  • CisplatinDrug

    IV Infusion

  • CarboplatinDrug

    IV Injection

  • CarboplatinDrug

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: Best Overall Response (BOR) of Complete Response (CR)/Partial Response (PR)Time frame: Up to 21 Months
  2. Stage 2: Overall Survival (OS)Time frame: Up to 55 Months

Locations

61 sites in 12 countries. Site status is shown where the registry gives one.

  • UC San Diego Health - Moores Cancer Center /ID# 267782

    La Jolla, California

  • Memorial Hospital West /ID# 262221

    Pembroke Pines, Florida

  • Bond Clinic /ID# 262611

    Winter Haven, Florida

  • University Cancer and Blood Cent /ID# 261824

    Athens, Georgia

  • The University of Chicago Medical Center /ID# 262259

    Chicago, Illinois

  • University of Kansas Medical Center /ID# 263196

    Westwood, Kansas

  • Baptist Health Lexington /ID# 261823

    Lexington, Kentucky

  • Cancer & Hematology Centers of Western Michigan - East /ID# 261826

    Grand Rapids, Michigan

  • Washington University School Of Medicine - Siteman Cancer Center /ID# 262759

    St Louis, Missouri

  • Stony Brook Cancer Center /ID# 261954

    Stony Brook, New York

  • Cone Health Cancer Center /ID# 262583

    Greensboro, North Carolina

  • Oncology Hematology Care, Inc - Blue Ash /ID# 262733

    Cincinnati, Ohio

  • Guthrie Robert Packer Hospital /ID# 262758

    Sayre, Pennsylvania

  • Renovatio clinical /ID# 262000

    El Paso, Texas

  • Houston Methodist Hospital /ID# 262722

    Houston, Texas

  • Texas Oncology - Plano East /ID# 264356

    Plano, Texas

  • Texas Oncology - San Antonio Medical Center - Research Drive /ID# 264311

    San Antonio, Texas

  • Renovatio Clinical /ID# 261999

    The Woodlands, Texas

  • Vista Oncology - East Olympia /ID# 262303

    Olympia, Washington

  • Canberra Hospital /ID# 261891

    Garran, Australian Capital Territory, Australia

  • Nepean Hospital /ID# 262157

    Kingswood, New South Wales, Australia

  • Westmead Hospital /ID# 261894

    Westmead, New South Wales, Australia

  • AZ Maria Middelares /ID# 262313

    Ghent, Belgium

  • Groupe Sante CHC - Clinique du MontLegia /ID# 262338

    Liège, Belgium

  • UCL Namur University Hospital, Site Sainte-Elisabeth /ID# 262557

    Namur, Belgium

  • Universitair Ziekenhuis Antwerpen /ID# 261270

    Edegem, Antwerpen, Belgium

  • Cliniques Universitaires UCL Saint-Luc /ID# 261267

    Brussels, Brussels Capital, Belgium

  • Hospital La Louviere Site Jolimont - Helora /ID# 261269

    La Louvière, Hainaut, Belgium

  • Hospital Clinico Universidad De Los Andes /ID# 262665

    Santiago, Chile

  • Centro de Investigacion y Desarrollo Oncologico /ID# 261800

    Temuco, Araucania, Chile

  • Oncored /Id# 261801

    Vitacura, Region Metropolitana Santiago, Chile

  • Fundacion Arturo Lopez Perez /ID# 261700

    Providencia, Santiago Metropolitan, Chile

  • Sociedad Cem-Cancer Spa /Id# 262316

    Viña del Mar, Valparaiso, Chile

  • Assistance Publique Hopitaux de Marseille - Hopital Nord /ID# 261129

    Marseille, Bouches-du-Rhone, France

  • CHU Grenoble - Hopital Michallon /ID# 261131

    La Tronche, Isere, France

  • Institut Curie /ID# 261127

    Paris, Paris, France

  • Hospices Civils de Lyon - Hopital Louis Pradel /ID# 261644

    Bron, Rhone, France

  • Centre Hosp Intercommunal de Creteil /ID# 261130

    Créteil, Val-de-Marne, France

  • Rambam Health Care Campus /ID# 262431

    Haifa, Israel

  • Shaare Zedek Medical Center /ID# 262432

    Jerusalem, Jerusalem, Israel

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.